TITLE

Tissue transplantation

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS107
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `Hepatocellular carcinoma in ursodeoxycholic acid treated primary biliary cirrhosis,' by J. Turner et al.
ACCESSION #
9708176443

 

Related Articles

  • Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. Kuiper, Edith M. M.; Hansen, Bettina E.; Metselaar, Herold J.; de Man, Robert A.; Haagsma, Els B.; van Hoek, Bart; van Buuren, Henk R. // BMC Gastroenterology;2010, Vol. 10, p144 

    Background: A decrease in the need for liver transplantations (LTX) in Primary Biliary Cirrhosis (PBC), possibly related to treatment with ursodeoxycholic acid (UDCA), has been reported in the USA and UK. The aim of this study was to assess LTX requirements in PBC over the past 20 years in the...

  • Prospective Randomized Trial of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid for Prevention of Radiation-Induced Liver Toxicity. Seidensticker, Max; Seidensticker, Ricarda; Damm, Robert; Mohnike, Konrad; Pech, Maciej; Sangro, Bruno; Hass, Peter; Wust, Peter; Kropf, Siegfried; Gademann, Günther; Ricke, Jens // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Background/Aim: Targeted radiotherapy of liver malignancies has found to be effective in selected patients. A key limiting factor of these therapies is the relatively low tolerance of the liver parenchyma to radiation. We sought to assess the preventive effects of a combined regimen of...

  • U12, a UDCA Derivative, Acts as an Anti-Hepatoma Drug Lead and Inhibits the mTOR/S6K1 and Cyclin/CDK Complex Pathways. Xu, Yang; Luo, Qiang; Lin, Ting; Zeng, Zhiping; Wang, Guanghui; Zeng, Dequan; Ding, Rong; Sun, Cuiling; Zhang, Xiao-kun; Chen, Haifeng // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    U12, one of 20 derivatives synthesized from ursodeoxycholic acid (UDCA), has been found to have anticancer effects in liver cancer cell lines (SMMC-7721 and HepG2) and to protect normal liver cells from deoxycholic acid (DCA) damage (QSG-7701). Its anticancer mechanism was investigated using...

  • Use of ursodeoxycholic acid in the treatment of arteriohepatic dysplasia. Kay, Marsha H.; Wyllie, Robert // Clinical Pediatrics;Nov1996, Vol. 35 Issue 11, p593 

    Focuses on the use of ursodeoxycholic acid as a cholesterol-lowering agent in two patients with arteriohepatic dysplasia. Patient reports.

  • Effect of Ursodeoxycholic Acid Administration in Patients with Primary Hypercholesterolaemia. Cicognani, C.; Malavolti, M.; Morselli-Labate, A.M.; Talarico, R.; Zamboni, L.; Sama, C. // Clinical Drug Investigation;1999, Vol. 18 Issue 4, p263 

    Objective: A high plasma cholesterol level is a major predisposing factor for coronary artery disease, and new treatments are currently under consideration. Supported by the close relationship between cholesterol and bile acid metabolism, recent studies have reported a hypocholesterolaemic...

  • The Long-term Beneficial Effects of Ursodeoxycholic Acid in Primary Biliary Cirrhosis are Highly Questionable. Gong Yan; Erik, Christensen; Gluud, Christian // American Journal of Gastroenterology;Feb2007, Vol. 102 Issue 2, p464 

    A letter to the editor is presented in response to article about the long-term effects of ursodeoxycholic acid on people with primary biliary cirrhosis.

  • Ursolic Acid of Origanum majorana L. Reduces Aβ-induced Oxidative Injury. Ho-Jin Heo; Hong-Yon Cho; Bumshik Hong; Hye-Kyung Kim; Tae-Ryeon Heo; Eun-Ki Kim; Sung-Koo Kim; Chang-Ju Kim; Dong-Hoon Shin // Molecules & Cells (Springer Science & Business Media B.V.);2002, Vol. 13 Issue 1, p5 

    Presents a study that investigated the effect of ursolic acid from Origanum majorana L. on A beta-induced neurotoxicity. Methodology; Results; Discussion.

  • Ursodeoxycholic acid and primary biliary cirrhosis. Lim, A.G.; Northfield, T.C. // BMJ: British Medical Journal (International Edition);8/20/94-8/27/94, Vol. 309 Issue 6953, p491 

    Focuses on the use of ursodeoxycholic acid in primary biliary cirrhosis. Effects of the drug on the pathophysiology of the disease; Decrease in the retention of bile acids; Reduction in the damage caused by hydrophobic bile acids.

  • Gallstone drug also prevents formation during rapid weight loss.  // Modern Medicine;Aug94, Vol. 62 Issue 8, p20 

    Reports on the use of the drug Ursodiol (ursodeoxycholic acid) in gallstone formation during rapid weight loss. Toleration to the drug; Adverse effects; Dosage.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics